The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis

References

• Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499–2510. doi:10.1056/NEJMoa1007903
   PubMed Web of Science ®Google Scholar
• Investigators E-P, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287–1297. doi:10.1056/NEJMoa1113572
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891. doi:10.1056/NEJMoa1009638
   PubMed Web of Science ®Google Scholar
• Weitz JI, Semchuk W, Turpie AG, Fisher WD, Kong C, Ciaccia A, Cairns JA. Trends in prescribing oral anticoagulants in Canada, 2008–2014. Clin Ther 2015;37:2506–14 e4. doi:10.1016/j.clinthera.2015.09.008
   PubMed Web of Science ®Google Scholar
• Loo SY, Dell’Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol 2017. doi:10.1111/bcp.13299
   PubMed Web of Science ®Google Scholar
• van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124:1968–1975. doi:10.1182/blood-2014-04-571232
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–962. doi:10.1016/S0140-6736(13)62343-0
   PubMed Web of Science ®Google Scholar
• Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke 2017;12:589–596. doi:10.1177/1747493017700663
   PubMed Web of Science ®Google Scholar
• Alotaibi GS, Almodaimegh H, McMurtry MS, Wu C. Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis. Thromb Res 2013;132:185–189. doi:10.1016/j.thromres.2013.07.017
   PubMed Web of Science ®Google Scholar
• De Crem N, Peerlinck K, Vanassche T, Vanheule K, Debaveye B, Middeldorp S, Verhamme P, Peetermans M. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res 2015;136:749–753. doi:10.1016/j.thromres.2015.07.030
   PubMed Web of Science ®Google Scholar
• Ferreira M, Barsam S, Patel JP, Czuprynska J, Roberts LN, Patel RK, Arya R. Heavy menstrual bleeding on rivaroxaban. Br J Haematol 2016;173:314–315. doi:10.1111/bjh.13583
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Michalski F, Tittl L, Hauswald-Dorschel S, Marten S. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. Lancet Haematol 2016;3:e480–e8. doi:10.1016/S2352-3026(16)30111-9
   PubMed Web of Science ®Google Scholar
• Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh EY, Becker RC, Singer DE, Halperin JL, Hankey GJ, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin ROCKET AF Trial. J Am Coll Cardiol 2015;66:2271–2281. doi:10.1016/j.jacc.2015.09.024
   PubMed Web of Science ®Google Scholar
• Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Trajanovic M, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2016;127:1417–1425. doi:10.1182/blood-2015-08-665927
   PubMed Web of Science ®Google Scholar
• Perzborn E, Kubitza D, Misselwitz FR. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Hamostaseologie 2007;27:282–289.
   PubMedGoogle Scholar
• Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV Jr., Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature 1998;394:690–694. doi:10.1038/29325
   PubMed Web of Science ®Google Scholar
• Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost 2003;1:1495–1503.
   PubMed Web of Science ®Google Scholar
• Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med 2008;14:429–440. doi:10.1016/j.molmed.2008.08.001
   PubMed Web of Science ®Google Scholar
• Blann AD, Lip GY, Beevers DG, McCollum CN. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997;77:1077–1080.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Cerletti C, Harrison P, Hayward CP, Kenny D, Nugent D, Nurden P, Rao AK, Schmaier AH, Watson SP, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Thromb Haemost 2013. doi:10.1111/jth.12231
   Web of Science ®Google Scholar
• Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927–929.
   PubMed Web of Science ®Google Scholar
• Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010;104:1078–1079. doi:10.1160/TH10-03-0204
   PubMed Web of Science ®Google Scholar
• De Jong A, Eikenboom J. Developments in the diagnostic procedures for von Willebrand disease. J Thromb Haemost 2016;14:449–460. doi:10.1111/jth.13243
   PubMed Web of Science ®Google Scholar
• Castaman G, Tosetto A, Cappelletti A, Goodeve A, Federici AB, Batlle J, Meyer D, Goudemand J, Eikenboom JC, Schneppenheim R, et al. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. Thromb Res 2010;126:227–231. doi:10.1016/j.thromres.2010.06.013
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc B Met 1995;57:289–300.
   Web of Science ®Google Scholar
• Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007;5:886–888. doi:10.1111/j.1538-7836.2007.02429.x
   PubMed Web of Science ®Google Scholar
• Banovcin P Jr., Skornova I, Samos M, Schnierer M, Bolek T, Kovar F, Stasko J, Kubisz P, Mokan M. Platelet aggregation in direct oral factor Xa inhibitors-treated patients with atrial fibrillation: a pilot study. J Cardiovasc Pharmacol 2017;70:263–266. doi:10.1097/FJC.0000000000000516
   PubMed Web of Science ®Google Scholar
• Eller T, Busse J, Dittrich M, Flieder T, Alban S, Knabbe C, Birschmann I. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clin Chem Lab Med 2014;52:835–844. doi:10.1515/cclm-2013-0936
   PubMed Web of Science ®Google Scholar
• Tsantes AE, Kyriakou E, Ikonomidis I, Katogiannis K, Papadakis I, Douramani P, Kopterides P, Kapsimali V, Lekakis J, Tsangaris I, et al. Comparative assessment of the anticoagulant activity of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation: a noninterventional study. Medicine 2016;95:e3037. doi:10.1097/MD.0000000000003037
   PubMed Web of Science ®Google Scholar
• Steppich B, Dobler F, Brendel LC, Hessling G, Braun SL, Steinsiek AL, Deisenhofer I, Hyseni A, Roest M, Ott I. Effect of the FXa inhibitors rivaroxaban and apixaban on platelet activation in patients with atrial fibrillation. J Thromb Thrombolysis 2017;43:490–497. doi:10.1007/s11239-017-1495-z
   PubMed Web of Science ®Google Scholar
• Zemer-Wassercug N, Haim M, Leshem-Lev D, Orvin KL, Vaduganathan M, Gutstein A, Kadmon E, Mager A, Kornowski R, Lev EI. The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers. J Thromb Thrombolysis 2015;40:340–346. doi:10.1007/s11239-015-1245-z
   PubMed Web of Science ®Google Scholar
• Olivier CB, Weik P, Meyer M, Weber S, Anto-Michel N, Diehl P, Zhou Q, Geisen U, Bode C, Moser M. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. Thromb Res 2016;138:63–68. doi:10.1016/j.thromres.2015.10.038
   PubMed Web of Science ®Google Scholar
• Perzborn E, Heitmeier S, Laux V. Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther 2015;20:554–562. doi:10.1177/1074248415578172
   PubMed Web of Science ®Google Scholar
• Nehaj F, Sokol J, Ivankova J, Mokan M, Kovar F, Stasko J, Mokan M. First evidence: TRAP-induced platelet aggregation is reduced in patients receiving Xabans. Clin Appl Thromb Hemost 2017. doi:10.1177/1076029617734310
   Web of Science ®Google Scholar